Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Now that the shortage of semaglutide injection products has been resolved, the Food and Drug Administration (FDA) will restrict third parties ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

Wegovy contains the same main ingredient as Ozempic, semaglutide, and is FDA-approved for weight loss in people with obesity or who are overweight with at least one weight-related condition. It is ...

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

The offer may show employers how hard drug manufacturers will compete based on price, in at least some situations.

On February 21, 2025, the US Food and Drug Administration (FDA) revised its shortage categorization of semaglutide, a glucagon-like peptide 1 ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight loss drugs Mounjaro and Zepbound, in a matter of days. That’s because a ...

The federal agency’s new alert is about counterfeit drugs claiming to have semaglutide — the key ingredient in weight loss ...

The U.S. Food and Drug Administration said on Monday it will not take action against compounding pharmacies making copies of ...

Novo Nordisk is introducing a direct-to-patient delivery option for its flagship weight loss drug Wegovy (semaglutide), ...